Pitfalls in the economic evaluation of thrombolysis in myocardial infarction The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups | Zendy

Roberto Lorenzoni | Zendy

Open Access

Pitfalls in the economic evaluation of thrombolysis in myocardial infarction The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups

Author(s) -

Roberto Lorenzoni

Publication year - 1998

Publication title -

european heart journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.336

H-Index - 293

eISSN - 1522-9645

pISSN - 0195-668X

DOI - 10.1053/euhj.1998.1092

Subject(s) - streptokinase , medicine , myocardial infarction , thrombolysis , tissue plasminogen activator , plasminogen activator , t plasminogen activator , recombinant dna , cardiology , surgery , biology , biochemistry , gene

The economic evaluation of the results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Artery (GUSTO) trial found that recombinant tissue plasminogen activator is more cost-effective than streptokinase for the treatment of acute myocardial infarction.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research